...The Arikace® study can provide valuable preliminary information as to the efficacy of inhaled liposomal amikacin in decreasing quantitative sputum mycobacterial cultures. Such data can then potentially be used in larger CF-focused interventional studies on the use of Arikace® as a chronic suppressive inhaled antibiotic to decrease, or even eradicate, the quantity of mycobacterial organisms in the CF lung.
08:30-10:00 Symposium 13 - New Inhaled Therapies
Moderators: C. Barreto (PT) / K. Van der Ent (NL)
Inhaled antibiotics – P. Flume (US)
Anticholinergics – Felix Ratjen (CA)